BiotechTube

Eftilagimod Alfa (Efti) + Docetaxel-cyclophosphamide (TC) intravenous (i.v) + Dose dense Adriamycin-cyclophosphamide (AC) i.v

Phase 2Recruiting
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Breast Cancer

Conditions

Breast Cancer, HER 2 Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, Stage 1-3

Trial Timeline

May 1, 2026 → Aug 1, 2028

NCT ID
NCT07102940

About Eftilagimod Alfa (Efti) + Docetaxel-cyclophosphamide (TC) intravenous (i.v) + Dose dense Adriamycin-cyclophosphamide (AC) i.v

Eftilagimod Alfa (Efti) + Docetaxel-cyclophosphamide (TC) intravenous (i.v) + Dose dense Adriamycin-cyclophosphamide (AC) i.v is a phase 2 stage product being developed by Immutep for Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07102940. Target conditions include Breast Cancer, HER 2 Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT07102940Phase 2Recruiting

Competing Products

20 competing products in Breast Cancer

See all competitors
ProductCompanyStageHype Score
LymphoseekNavidea BiopharmaceuticalsPhase 3
69
LymphoseekNavidea BiopharmaceuticalsPhase 3
69
ALT-P7 (HM2-MMAE)AlteogenPhase 1
33
Biomarkers blood, urine and microbiota samplesEli LillyPre-clinical
23
gemcitabine + paclitaxel + bevacizumabEli LillyPhase 2
52
Gemcitabine + Adriamycine + PaclitaxelEli LillyPhase 2
52
Abemaciclib + FulvestrantEli LillyPhase 2
52
VS-6766 + Abemaciclib + FulvestrantEli LillyPhase 1/2
41
gemcitabine + vinorelbineEli LillyPhase 2
52
Abemaciclib + Fulvestrant + PlaceboEli LillyPhase 3
77
Azenosertib + Carboplatin + PembrolizumabZentalis PharmaceuticalsPhase 1/2
33
AbemaciclibEli LillyPre-clinical
23
pemetrexed + cyclophosphamide + doxorubicin + docetaxelEli LillyPhase 2
52
arzoxifeneEli LillyApproved
85
BBI-355 + Erlotinib + Futibatinib + BBI-825Boundless BioPhase 1
25
BBI-940 + FulvestrantBoundless BioPhase 1
25
LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + FulvestrantEli LillyPhase 3
77
pemetrexed + gemcitabineEli LillyPhase 2
52
Experimental Arm A: Pemetrexed + Experimental Arm A: Sorafenib + Experimental Arm B: Pemetrexed + Experimental Arm B: SorafenibEli LillyPhase 2
52
pemetrexedEli LillyPhase 2
52

Other Products from Immutep

eftilagimod alpha + PaclitaxelPhase 2/3
57
Pembrolizumab, Eftilagimod alfaPhase 2
44
IMP321 (eftilagimod alpha) + Placebo + PaclitaxelPhase 2
44
2 vaccine injections in 1 limb + 2 vaccine injections in distinct limbs + 2 "vaccine injections" in distinct limbsPhase 1/2
33
Immunological peptides and immunological adjuvants + HLA-A2 peptides + Montanide ISA51 + IMP321Phase 1/2
33